ADX-097 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Read More

6 minute read

Pharma Industry News

Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline

Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook.

bySoujanya Ravi

December 1, 2025

web analytics